Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo

The Journal of Infectious Diseases
J E CroweG R Pilkington

Abstract

A second human respiratory syncytial virus (RSV)-neutralizing monoclonal antibody was isolated and its binding site was identified. Fab F2-5 is a broadly reactive fusion (F) protein-specific recombinant Fab generated by antigen selection from a random combinatorial library displayed on the surface of filamentous phage. In an in vitro plaque-reduction test, the Fab RSVF2-5 neutralized the infectivity of a variety of field isolates representing viruses of both RSV subgroups A and B. The Fab recognized an antigenic determinant that differed from the only other human anti-F monoclonal antibody (RSV Fab 19) described thus far. A single dose of 4.0 mg of Fab RSVF2-5/kg of body weight administered by inhalation was sufficient to achieve a 2000-fold reduction in pulmonary virus titer in RSV-infected mice. The antigen-binding domain of Fab RSVF2-5 offers promise as part of a prophylactic regimen for RSV infection in humans.

Citations

Dec 1, 1999·Reviews in Medical Virology·M Zambon
May 7, 1999·Immunotechnology : an International Journal of Immunological Engineering·M HanssonP A Nygren
Apr 10, 2012·Current Opinion in Virology·Damian C Ekiert, Ian A Wilson
Jul 28, 2010·Biotechnology Advances·Jyoti PandeAshok K Grover
Mar 11, 2008·Journal of Immunological Methods·D MolinkováV Celer
Nov 3, 2016·Proceedings of the National Academy of Sciences of the United States of America·Jarrod J MousaJames E Crowe
Jun 27, 2013·Nanotechnology·John W StoneJames E Crowe
Feb 23, 2018·PLoS Pathogens·Jarrod J MousaJames E Crowe

❮ Previous
Next ❯

Related Concepts

Related Feeds